Bench to Boardroom

In this episode of Bench to Boardroom, we explore why the probability of success in biopharma extends far beyond the science itself. While the industry is built on evidence and innovation, investment and portfolio decisions do not always follow rational, probability-adjusted thinking. The discussion examines how clinical development strategy, endpoint selection, regulatory clarity, investor sentim...

In this episode of Bench to Boardroom, we examine why so many biopharma launches fail to meet expectations despite unprecedented access to data, analytics, and technology. Using the lens of the approximately 34% of U.S. launches that miss forecast and the widespread industry view that poor data are a key contributor, the discussion explores the deeper root causes of underperformance -- including t...

In this episode of Bench to Boardroom, we examine why maximizing value across a life sciences portfolio increasingly requires an asset-specific, geography-agnostic approach rather than relying on the traditional “U.S. first, Europe second, rest of world later” launch model. Through examples in oncology/hematology, cell and gene therapy, and immunology, the discussion explores how launch sequencing...

In this episode of Bench to Boardroom, we explore why not all technology investments in life sciences are created equal — and why following the hype around AI and digital transformation may generate far weaker returns than many executives expect. The discussion examines where emerging technologies can create meaningful strategic advantage across clinical development, commercialization, market acce...

Launching innovative medicines can no longer follow conventional precedent. The old formula -- U.S. first, Europe second, rest of world later -- is increasingly misaligned with the realities of today’s health policy, pricing, and market access environment. And for some assets, following the traditional launch sequence may actually destroy long-term value. Not because the science is flawed. But bec...

The term Portfolio Strategy gets used constantly in life sciences. Board decks use it. Investors use it. Management teams use it. Consultants use it. But too often, portfolio strategy is treated as a static spreadsheet exercise -- ranking assets, cutting budgets, and reallocating headcount. In this episode, we discuss why (and how) real portfolio strategy is far more consequential than that.

Short trailer introducing the Bench to Boardroom podcast